In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.
Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.
Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.
Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.